NCT03785548 is a clinical trial of Usage of a mirror in Pelvic Exam, sponsored by TriHealth Inc..

Who is sponsoring NCT03785548?

NCT03785548 is sponsored by TriHealth Inc..

What drugs are being tested in NCT03785548?

Interventions in NCT03785548: Usage of a mirror.

What condition does NCT03785548 study?

NCT03785548 studies Pelvic Exam.

Is NCT03785548 still recruiting?

NCT03785548 is currently completed. Last updated 17 August 2020.

Are results published for NCT03785548?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-08-17 · How we verify

NCT03785548

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Utilization of the Mirror During Pelvic Exams

Completed Results posted Last updated 17 August 2020

What this trial tests

trial testing Usage of a mirror in Pelvic Exam in 147 participants. Completed in 1 July 2020.

Timeline

15 April 2019

Primary endpoint
29 May 2020

1 July 2020

Quick facts

Lead sponsor	TriHealth Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	147
Start date	15 April 2019
Primary completion	29 May 2020
Estimated completion	1 July 2020
Sites	1 location across United States

Drugs / interventions tested

Usage of a mirror

Conditions studied

Pelvic Exam — all drugs for Pelvic Exam →

Sponsor

TriHealth Inc. — full company profile →

Who can join

Adults 18 to 80, female only, with Pelvic Exam. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Group Difference in Visual Analog Scale (VAS) on Level of Vulnerability Primary · 30 minutes after the pelvic exam

VAS on vulnerability level will be measured after the pelvic exam, and group difference after controlling for baseline vulnerability, will be calculated. The VAS is a validated 100 millimeter scale with 'no vulnerability' represented as 0 mm and 'very vulnerable' equating to 100 mm.

Group	Value	95% CI
Mirror Group	13.294	± 1.854
No Mirror Group	16.145	± 1.789

Group Difference in Visual Analog Scale (VAS) on Level of Pain/Discomfort Primary · 30 minutes after the pelvic exam

VAS on discomfort level will be measured after the pelvic exam, and group difference after controlling for baseline discomfort level, will be calculated. The VAS is a validated 100 millimeter scale with 'no pain' represented as 0 mm and 'most pain' equating to 100 mm.

Group	Value	95% CI
Mirror Group	19.683	± 2.201
No Mirror Group	19.824	± 2.154

Sponsor's own description

This is a prospective cohort study to determine if using a birthing mirror during the patient's pelvic examination decreases patients's degree of vulnerability and discomfort.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Utilization of a Mirror During Pelvic Examinations: Does it Improve the Patient's Experience?
Tam T, Crisp CC, Hill AM, Aldrich E, et al · · 2021 · cited 2× · PMID 33620906 · DOI 10.1097/spv.0000000000000975

Verify or expand the search:

Other TriHealth Inc. trials

Trials by the same sponsor.

NCT07017920 — Vitamin D and Hypertensive Disorders of Pregnancy · NA · not yet recruiting
NCT06843538 — Peri-operative Tamsulosin and Impact on Voiding Trial After Same-day Urogynecology Surgery · Phase 3 · recruiting
NCT06958003 — Neonatal Intensive Care Unit (NICU) Diaper Dermatitis: Prevention and Treatment With Airtime · NA · enrolling by invitation
NCT06957990 — Evaluation of Music Therapy for Pre-op/Intra-op During Hernia Surgery to Decrease the Need for Narcotics · NA · enrolling by invitation
NCT06414083 — Histologic Comparison of Ablative Techniques for Endometriosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03785548 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by TriHealth Inc.
Last refreshed: 17 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03785548.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing